FGF19 and metabolic dysfunction-associated steatotic liver disease: We know that the overexpression of FGF19 has been observed in patients with cirrhosis, NAFLD, PBC, precancerous condition, and HCC [13,27,30] and that FGF19 is a factor whose concentration tends to increase depending on the severity of pathological conditions with the significantly higher level of FGF19 in HCC patients [27].